$TVRD News

Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate

Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf

Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4

Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Tvardi Therapeutics Provides Updates From Phase 2 REVERT IPF Clinical Trial Of TTI-101 In Idiopathic Pulmonary Fibrosis

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi: Q3 Earnings Snapshot

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now

Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround